Deep TMS News - Get The Latest News On BrainsWay's Deep TMS

News & Events

November 1, 2022

BrainsWay Appoints Dr. Colleen A. Hanlon as Vice President of Medical Affairs

Dr. Hanlon has Served as a Leader in Brain Stimulation Research for Nearly 20 Years BURLINGTON, Mass....

October 12, 2022

BrainsWay Launches Social Media Sweepstakes in Observance of Depression Awareness Month

The sweepstakes aims to raise awareness of Deep TMS™ as a treatment option for mental health disorders...

October 11, 2022

BrainsWay and NOCD Launch Collaboration to Increase Awareness of OCD Treatments

BURLINGTON, Mass. and JERUSALEM, Oct. 11, 2022 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

September 20, 2022

BrainsWay CEO Christopher von Jako Named Honorary Chair of NAMIWalks Silicon Valley

BURLINGTON, Mass. and JERUSALEM, Sept. 20, 2022 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

September 14, 2022

BrainsWay Announces Private Insurance Coverage from Cigna Corporation for OCD Treatment

Cigna® Issues Favorable Policy for Deep TMS to Address Medication-Resistant Obsessive-Compulsive Disorder BURLINGTON,...

August 31, 2022

BrainsWay to Present at the H.C. Wainwright Annual Global Investment Conference

BURLINGTON, Mass. and JERUSALEM, August 31, 2022 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

August 29, 2022

BrainsWay Receives New FDA Clearance for Treating Depression and Anxious Depression

Depression Clearance for the Proprietary Deep TMS™ H7 Coil Represents the Company’s 9th FDA Clearance BURLINGTON,...

August 10, 2022

BrainsWay Reports Second Quarter 2022 Financial Results and Operational Highlights

Revenue Growth of 14% Year-over-Year in Q2 2022 Conference call to be held today, August 10, 2022, at...

July 27, 2022

BrainsWay to Report Second Quarter Financial Results on August 10, 2022

BURLINGTON, Mass. and JERUSALEM, July 27, 2022 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

June 28, 2022

BrainsWay Announces Insurance Coverage by Israeli Ministry of Health for the Treatment of Depression

The Company’s Groundbreaking Deep TMS™ Treatment is Included in Israel’s Health Basket of Essential...

June 23, 2022

BrainsWay Donates $10,000 to Mental Health America in Support of Mental Health Awareness Month

BURLINGTON, Mass. and JERUSALEM, Israel, June 23, 2022 – BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay”...

June 22, 2022

BrainsWay to Present at the H.C. Wainwright 1st Annual Mental Health Conference

BURLINGTON, Mass. and JERUSALEM, June 22, 2022 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

June 21, 2022

BrainsWay Announces Positive OCD Coverage Policy from Blue Cross Blue Shield® (BCBS) Licensee Highmark BCBS for Deep TMS™

Highmark BCBS Covers 6.8 Million Members in Four States BURLINGTON, Mass. and JERUSALEM, June 21, 2022...

May 11, 2022

BrainsWay Reports First Quarter 2022 Financial Results and Operational Highlights

Revenue Growth of 30% Year-over-Year in Q1 2022 Conference call to be held today, May 11, 2022, at 8:30...

May 9, 2022

BrainsWay Appoints Eric Hirt as Vice President of U.S. Sales

Veteran Medical Device Industry Sales and Marketing Executive Has Over 20 Years of Experience BURLINGTON,...

May 4, 2022

BrainsWay to Present Expanded Post-Marketing Clinical Research for Major Depressive Disorder at Clinical TMS Society

Additional presentations will highlight the utility of Deep TMS™ in Smoking Addiction and OCD BURLINGTON,...

May 2, 2022

BrainsWay Launches #DontMissAnotherMoment Social Media Campaign to Promote Mental Health Awareness Month

BrainsWay will donate $5 per share, $2 per comment, and $1 per like to support the work of Mental Health...

April 27, 2022

BrainsWay to Report First Quarter Financial Results on May 11, 2022

BURLINGTON, Mass. and JERUSALEM, April 27, 2022 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

Find a provider near you or contact us today.

Find a Provider Contact Us